With COVID shining a light on the importance of innovation in medicine with a focus on unmet needs, read Ross’ view on the work being done to improve the effectiveness of drugs and treatments, and to reduce their side effects:
CEO Dr Ross Macdonald joined ausbiz to discuss the development and the outlook for Cynata in 2022 following the receipt of a patent from Japan, the world’s second largest stem cell market.
Providing hope for people with diabetic foot ulcers (DFU), Cynata’s Phase I trial of CYP‑006TK has commenced and is now open for patient enrolment:
Investing in medical research projects with the potential to deliver better health outcomes to more Australians is a government priority with the Morrison government investing more than $25m through the Biomedical Translation Fund three, in cutting-edge companies including Cynata:
In big news, Cynata has inked a Manufacturing Services Agreement with Fujifilm Cellular Dynamics to manufacture and supply its Cymerus™ MSCs. Cynata CEO Dr Ross Macdonald sat down with Eddy Sunarto at Stockhead to discuss just how important this deal is for the Company